U.S. lawmakers introduced bipartisan legislation to create a National Biopharmaceutical Manufacturing Center of Excellence (COE) to accelerate domestic manufacturing methods, regulatory understanding and workforce training for products tied to national and health security. Complementing policy, Thermo Fisher Scientific opened an East Coast Advanced Therapies Collaboration Center in Philadelphia to support cell and gene therapy development. The combined policy and infrastructure moves aim to shrink supply‑chain risk and scale advanced therapy manufacturing domestically.